Study Stopped
An interim analysis revealed a significantly higher persistence/recurrence of complications of portal hypertension in the 8 mm-stent group.
Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents
Clinical Efficacy of Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents in Cirrhotic Patients: A Randomized Controlled Study
1 other identifier
interventional
44
1 country
1
Brief Summary
Coated stents with different diameters are presently commercially available, but clinical studies on the assessment of the best stent diameter for a better clinical efficacy, a reduced number of complications, and an effective portal pressure reduction (essential in the treatment of those pathologies in which TIPS is indicated) still do not exist. Aim of the study The purpose of our study is to compare the clinical efficacy and the incidence of complications of TIPS created with 8- and 10-mm covered stents in patients with hepatic cirrhosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Jan 2006
Typical duration for phase_2
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2006
CompletedFirst Submitted
Initial submission to the registry
November 17, 2006
CompletedFirst Posted
Study publicly available on registry
November 22, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2008
CompletedJanuary 9, 2009
January 1, 2009
2.8 years
November 17, 2006
January 8, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
hepatic encephalopathy incidence:
1 year
Secondary Outcomes (6)
incidence of persistent hepatic encephalopathy: defined as the presence of a continuous mental state alteration, with episodes of further worsening episodes;
one year
incidence of recurrent hepatic encephalopathy: defined as the onset of at least three episodes of open hepatic encephalopathy in a six-month period;
one year
incidence of variceal rebleeding: defined as the finding, at esophagogastroduodenoscopy, of ongoing or recent variceal hemorrhage or the finding of blood in the stomach and the presence of varices as the only potential cause of bleeding;
one year
shunt dysfunction: defined as the finding of a portosystemic gradient higher than 12 mm Hg and angiographic evidence of shunt stenosis or occlusion;
one year
recurrence of ascites: defined as the need of performing at least one evacuation of ascitic fluid with paracentesis;
one year
- +1 more secondary outcomes
Study Arms (2)
1
ACTIVE COMPARATORpatients treated with 10 mm stent
2
ACTIVE COMPARATORpatients treated with 8 mm stent
Interventions
creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
Eligibility Criteria
You may qualify if:
- All consecutive cirrhotic patients who have undergone TIPS at our Department for bleeding of esophagogastric varices refractory to medical or endoscopic treatment or for ascites/hydrothorax refractory to diuretic therapy will be considered eligible for the study.
You may not qualify if:
- an age \>75 years; past or present history of hepatic encephalopathy;
- a Z-score at trial making test-A (TMT-A) \>1.5;
- bilirubine levels \>5 mg/dl;
- creatinine levels \>3 mg/dl;
- serious cardiac or pulmonary dysfunction;
- a Child-Pugh's score \>11;
- a model end-stage liver disease (MELD) score \>18;
- portal thrombosis;
- a diagnosis of hepatic carcinoma;
- sepsis;
- spontaneous bacterial peritonitis;
- renal insufficiency.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Gastroenterology Unit. dip. Medicina Clinica Policlinico Umberto I
Roma, 00100, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Oliviero Riggio, MD
Gastroenterology Unit
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
November 17, 2006
First Posted
November 22, 2006
Study Start
January 1, 2006
Primary Completion
October 1, 2008
Study Completion
December 1, 2008
Last Updated
January 9, 2009
Record last verified: 2009-01